Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective—Brief Report
Across 6 US academic medical centers, evinacumab was generally well tolerated by patients with HoFH and lowered LDL-C by ≈50%, consistent with results from clinical trials.
Authors
- Prediman K. Shah (ORCID: https://orcid.org/0000-0002-6351-8291)
- Bruce A. Warden (ORCID: https://orcid.org/0000-0003-3635-7506)
- Michael J. Wilkinson (ORCID: https://orcid.org/0000-0002-3800-7369)
- Matthew K. Ito
- Eveline O. Stock (ORCID: https://orcid.org/0000-0001-7085-5790)
- Ron S. Newfield (ORCID: https://orcid.org/0000-0001-6274-8530)
- Michael Davidson (ORCID: https://orcid.org/0000-0002-4698-1719)
- Priyesha Bijlani (ORCID: https://orcid.org/0000-0002-9996-6686)
- Mary J. Malloy (ORCID: https://orcid.org/0000-0001-6189-5993)
- P. Barton Duell (ORCID: https://orcid.org/0000-0002-0208-5154)
- Mary Horan
- Pallavi Pradeep
Institutions
- Cedars-Sinai Medical Center (US)
- Oregon Health & Science University (US)
- Regeneron (United States) (US)
- University of California San Diego (US)
- University of Chicago (US)
- Rady Children's Hospital-San Diego (US)
- University of San Francisco (US)
Publication Details
- Journal
- Arteriosclerosis Thrombosis and Vascular Biology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1161/atvbaha.124.322364
- Citations
- 9
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 12.49